Codexis Inc (CDXS)

Currency in USD
3.110
-0.130(-4.01%)
Closed·
After Hours
3.1100.000(0.00%)
·
CDXS Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected in 5 days
Fair Value
Day's Range
3.0103.230
52 wk Range
1.9006.080
Key Statistics
Prev. Close
3.24
Open
3.23
Day's Range
3.01-3.23
52 wk Range
1.9-6.08
Volume
1.45M
Average Volume (3m)
864.46K
1-Year Change
-14.79%
Book Value / Share
0.6
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CDXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.083
Upside
+127.76%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Codexis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Codexis Inc Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Inc SWOT Analysis


Enzymatic Revolution
Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency
Market Opportunity
Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach
Financial Fortitude
Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million
Analyst Outlook
Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena
Read full SWOT analysis

Codexis Inc Earnings Call Summary for Q1/2025

  • Codexis Q1 2025 results: EPS -$0.25 (vs -$0.24 forecast), revenue $7.5M (vs $10.32M expected); stock down 10.16% after-hours
  • Revenue dropped from $17.1M in Q1 2024; product gross margin improved to 55%; cash position at $59.8M
  • 2025 revenue guidance set at $64-68M, below analyst expectations; significant revenue ramp anticipated in H2 2025
  • New machine learning tool for RNA fragment design launched; CEO highlights efficiency gains in production process
  • Challenges include revenue decline, increased net loss, and scaling production; CDMOs identified as primary early adopters
Last Updated: 14/05/2025, 22:32
Read Full Transcript

Compare CDXS to Peers and Sector

Metrics to compare
CDXS
Peers
Sector
Relationship
P/E Ratio
−3.5x−4.7x−0.5x
PEG Ratio
1.190.080.00
Price/Book
5.2x1.5x2.6x
Price / LTM Sales
5.2x1.7x3.2x
Upside (Analyst Target)
125.1%76.1%41.7%
Fair Value Upside
Unlock16.7%6.1%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.083
(+127.76% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.25 / -0.24
Revenue / Forecast
7.50M / 10.32M
EPS Revisions
Last 90 days

CDXS Income Statement

People Also Watch

7.390
BBAI
-5.26%
43.17
IONQ
-1.66%
15.440
RGTI
-3.20%
115.62
CRWV
-3.65%
21.72
BEAM
+3.68%

FAQ

What Stock Exchange Does Codexis Trade On?

Codexis is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Codexis?

The stock symbol for Codexis is "CDXS."

What Is the Codexis Market Cap?

As of today, Codexis market cap is 257.65M.

What Is Codexis's Earnings Per Share (TTM)?

The Codexis EPS (TTM) is -0.97.

When Is the Next Codexis Earnings Date?

Codexis will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is CDXS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Codexis Stock Split?

Codexis has split 0 times.

How Many Employees Does Codexis Have?

Codexis has 188 employees.

What is the current trading status of Codexis (CDXS)?

As of 26 Jul 2025, Codexis (CDXS) is trading at a price of 3.11, with a previous close of 3.24. The stock has fluctuated within a day range of 3.01 to 3.23, while its 52-week range spans from 1.90 to 6.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.